CLOs on the Move

ScriptPro LLC

www.scriptpro.com

 
ScriptPro LLC is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Mission, KS. To find more information about ScriptPro LLC, please visit www.scriptpro.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Shifamed

Shifamed is a Campbell, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

vision orlando inc

vision orlando inc is a Winter Park, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MiraVista Behavioral Health Center

MiraVista is a new behavioral health treatment center opening April 2021 in the former Providence Hospital in Holyoke, MA. The newly renovated center will initially provide adult psychiatric and addiction treatment and will expand capacity to include child and adolescent services by the end of the year. Our mission is to provide compassionate, effective, sustainable care for those suffering from psychiatric distress and substance abuse. We are committed to helping fill the critical need for quality behavioral care in the Pioneer Valley and are excited to open our doors this Spring.

Harvard Vanguard Medical Associates

At Harvard Vanguard Medical Associates, our staff is our most important resource. That's why we offer challenging work, career advancement, competitive salaries and a benefits program that is among the best in the marketplace. The following summary is

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.